Gehrke Leon, Seifert Nicole, Spieler Peter, Verbruggen Christina, Seifert Rick, Toppeta Fabio, Krick Maximilian, Doose Sören, Einsele Hermann, Hudecek Michael, Sauer Markus, Nerreter Thomas
Chair of Cellular Immunotherapy, Department of Internal Medicine II, University Hospital Würzburg (UKW), Würzburg, Germany.
Department of Biotechnology and Biophysics, Biocenter, Am Hubland, University of Würzburg, Würzburg, Germany.
Front Immunol. 2025 Aug 1;16:1632823. doi: 10.3389/fimmu.2025.1632823. eCollection 2025.
Chimeric antigen receptor (CAR) T cells are a transformative treatment for hematological malignancies, and concerted efforts in the field are aiming to translate this success to solid tumors and autoimmune diseases. There is a desire in the field to accurately assess CAR organization and spatiotemporal expression to elucidate mechanistic details of CAR-T cell mediated anti-tumor activity and enable evaluation of the potency and safety of CAR-T cell products. We applied an IgG4-targeted F(ab) to achieve direct CAR labeling for super-resolution microscopy by stochastic optical reconstruction microscopy (STORM). This enabled us to determine CAR surface expression on human primary T cells with single-molecule resolution independent of CAR specificity. We combined this direct CAR detection approach with a phenotypic assessment of the CAR-T cells, highlighting prospective applications to gain detailed mechanistic insights. With this new approach, we were able to detect the surface expression of CARs targeting SLAMF7, BCMA and CD19 with minimal background. We determined T cell subtype, donor material, and CAR construct as contributing factors shaping CAR surface expression and identified putative influence of CAR surface expression on CAR-T cell activation state. Here we provide a novel, tag-free approach to gain insights into the surface expression of CARs, illustrating the potential of super-resolution microscopy to inform the application of synthetic immune receptors for CAR-T cell therapy, potentially building the basis for more intricate and combinatorial studies to further improve the efficacy of CAR-T cell immunotherapy, predict therapeutic outcome and ensure optimal care for patients.
嵌合抗原受体(CAR)T细胞是血液系统恶性肿瘤的一种变革性治疗方法,该领域正在共同努力将这一成功应用于实体瘤和自身免疫性疾病。该领域希望准确评估CAR的组织形式和时空表达,以阐明CAR-T细胞介导的抗肿瘤活性的机制细节,并能够评估CAR-T细胞产品的效力和安全性。我们应用了一种靶向IgG4的F(ab)片段,通过随机光学重建显微镜(STORM)实现对CAR的直接标记,用于超分辨率显微镜观察。这使我们能够以单分子分辨率确定人原代T细胞上的CAR表面表达,而与CAR的特异性无关。我们将这种直接CAR检测方法与CAR-T细胞的表型评估相结合,突出了其在获取详细机制见解方面的潜在应用。通过这种新方法,我们能够以最小的背景检测靶向信号淋巴细胞激活分子家族成员7(SLAMF7)、B细胞成熟抗原(BCMA)和CD19的CAR的表面表达。我们确定T细胞亚型、供体材料和CAR构建体是影响CAR表面表达的因素,并确定了CAR表面表达对CAR-T细胞激活状态的潜在影响。在这里,我们提供了一种新颖的、无标签的方法来深入了解CAR的表面表达,展示了超分辨率显微镜在为CAR-T细胞疗法的合成免疫受体应用提供信息方面的潜力,这可能为更复杂和组合性的研究奠定基础,以进一步提高CAR-T细胞免疫疗法的疗效、预测治疗结果并确保为患者提供最佳护理。